StageZero Life Sciences Announces Conversion of December 2016 Convertible DebenturesHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)StageZero Life Sciences Announces Conversion of December 2016 Convertible DebenturesACCESSWIREJanuary 3, 2020ReblogShareTweetShareTHIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES.TORONTO, ON / ACCESSWIRE / January 3, 2020 / StageZero Life Sciences, Ltd (SZLS.TO) ("StageZero" or the "Company") today announced that it has exercised its conversion option for the brokered convertible, unsecured subordinated debentures (the "Debentures") maturing on December 23, 2019. Canadian $621,000 of outstanding Debentures were converted.The Debentures bore interest at a rate of 8% per annum, payable semi-annually in arrears, in cash, and the final interest payment has been made. Payment of principal was payable in cash or common shares of the Company ("Common Shares") at the discretion of the Company. The Company elected to pay in Common Shares, where the number of Common Shares delivered was at a 10% discount to the 5-day volume weighted average trading price ending on the trading day immediately preceding the date that the principal amount is due.Each Debenture will be converted into Common Shares at a conversion price of $0.03636 for a total issuance of 17, 078,742 shares. No fractional shares will be issued.This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of StageZero in the United States.About StageZero Life SciencesStageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle®, our next generation test, is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which has been validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. To learn more visit www.stagezerolifesciences.com.Forward-Looking StatementsThis press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.CONTACT:James R. Howard-TrippChairman & CEOjht@stagezerols.comTel: 1-855-420-7140 Ext. 1Jerome ClicheFinancial Communication AdvisorLMCCOM@videotron.caTel. (514) 815-8799SOURCE: StageZero Life Sciences LtdView source version on accesswire.com: https://www.accesswire.com/571942/StageZero-Life-Sciences-Announces-Conversion-of-December-2016-Convertible-DebenturesReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextAllied Esports withdraws planned public offeringAmerican City Business JournalsA new calculator sheds light on high-flying U.S. unicorn price tagsReutersPublic Storage (PSA) Q4 FFO & Revenues Miss Estimates, Up Y/YZacksRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo Finance'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo Finance